Vesugen completes the set of short "peptide bioregulators" in this library, with
a marketed focus on the vascular system.
Chemical identity & structure.
Vesugen is a synthetic tripeptide (lysine–glutamic acid–aspartic acid). It is
one of the tissue-targeted "peptide bioregulators" from the same Russian
research program as Pinealon, Cardiogen, and Epithalon.
Mechanism of action.
The proposed mechanism is the same family-wide hypothesis — that the very short
peptide interacts with DNA and influences gene expression in a tissue-associated
way. For Vesugen the claimed association is the vascular wall, with reported
support for the function of the cells lining blood vessels. This is a research-
program hypothesis, not an independently established pharmacology.
Key research findings.
Reported findings, from that program, describe effects on vascular-cell function
and age-related vascular markers in laboratory models.
The research / citation base.
As with the other bioregulators, the Vesugen literature is **dominated by a
single Russian research program with very limited independent replication.**
Vesugen is not approved by the FDA or EMA. The marketed vascular-health
claims are not supported by independent, Western-standard clinical evidence.
Administration.
No human clinical trial has established administration parameters for Vesugen; VialTalk does not provide community-sourced dosing.
Quality & sourcing notes.
A simple tripeptide is straightforward to verify for identity and purity by COA
(mass spectrometry; HPLC). The evidence base remains the real limitation.
*Research-use note: Educational summary of published research. Vesugen is not an
approved drug and its evidence base is limited; this is research context only
and not medical advice.*
